These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 21659416)

  • 41. [Metalloproteinase-9/tissue inhibitor of metalloproteinase-1 in induced sputum in patients with asthma and chronic obstructive pulmonary disease and their relationship to airway inflammation and airflow limitation].
    Xin XF; Zhao M; Li ZL; Song Y; Shi Y
    Zhonghua Jie He He Hu Xi Za Zhi; 2007 Mar; 30(3):192-6. PubMed ID: 17572998
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Matrix metalloproteinases and matrix metalloproteinase inhibitors in acute lung injury.
    Fligiel SE; Standiford T; Fligiel HM; Tashkin D; Strieter RM; Warner RL; Johnson KJ; Varani J
    Hum Pathol; 2006 Apr; 37(4):422-30. PubMed ID: 16564916
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Inhibition of matrix metalloproteinases prevents allergen-induced airway inflammation in a murine model of asthma.
    Kumagai K; Ohno I; Okada S; Ohkawara Y; Suzuki K; Shinya T; Nagase H; Iwata K; Shirato K
    J Immunol; 1999 Apr; 162(7):4212-9. PubMed ID: 10201949
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Children with stable asthma have reduced airway matrix metalloproteinase-9 and matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio.
    Doherty GM; Kamath SV; de Courcey F; Christie SN; Chisakuta A; Lyons JD; Heaney LG; Ennis M; Shields MD
    Clin Exp Allergy; 2005 Sep; 35(9):1168-74. PubMed ID: 16164443
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Relevance of tenascin-C and matrix metalloproteinases in vascular abnormalities in murine hypoplastic lungs.
    Chinoy MR; Miller SA
    Biol Neonate; 2006; 90(3):185-96. PubMed ID: 16699260
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Is there new hope for therapeutic matrix metalloproteinase inhibition?
    Vandenbroucke RE; Libert C
    Nat Rev Drug Discov; 2014 Dec; 13(12):904-27. PubMed ID: 25376097
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Anti-inflammatory and antifibrotic effects of resveratrol in the lung.
    Conte E; Fagone E; Fruciano M; Gili E; Iemmolo M; Vancheri C
    Histol Histopathol; 2015 May; 30(5):523-9. PubMed ID: 25515609
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Matrix metalloproteinases in destructive pulmonary pathology.
    Elkington PT; Friedland JS
    Thorax; 2006 Mar; 61(3):259-66. PubMed ID: 16227332
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Matrix metalloproteinases as drug targets in acute pulmonary embolism.
    Neto-Neves EM; Kiss T; Muhl D; Tanus-Santos JE
    Curr Drug Targets; 2013 Mar; 14(3):344-52. PubMed ID: 23316966
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Matrix metalloproteinases are involved in cardiovascular diseases.
    Azevedo A; Prado AF; Antonio RC; Issa JP; Gerlach RF
    Basic Clin Pharmacol Toxicol; 2014 Oct; 115(4):301-14. PubMed ID: 24974977
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Year in review 2013: Acute lung injury, interstitial lung diseases, sleep and physiology.
    Piper A; Song Y; Eves ND; Maher TM
    Respirology; 2014 Apr; 19(3):428-37. PubMed ID: 24708032
    [No Abstract]   [Full Text] [Related]  

  • 52. The matrix comes to lung transplantation.
    Babu AN; Nicolls MR
    Transplantation; 2007 Mar; 83(6):683-4. PubMed ID: 17414698
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Matrix Metalloproteinases as New Targets in Alzheimer's Disease: Opportunities and Challenges.
    Zipfel P; Rochais C; Baranger K; Rivera S; Dallemagne P
    J Med Chem; 2020 Oct; 63(19):10705-10725. PubMed ID: 32459966
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Matrix metalloproteinases in T cell mediated pulmonary diseases.
    Benson HL; Wilkes DS
    Front Biosci (Elite Ed); 2012 Jan; 4(6):2162-9. PubMed ID: 22202028
    [TBL] [Abstract][Full Text] [Related]  

  • 55. MMPs as therapeutic targets--still a viable option?
    Fingleton B
    Semin Cell Dev Biol; 2008 Feb; 19(1):61-8. PubMed ID: 17693104
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Matrix metalloproteinases as valid clinical targets.
    Fingleton B
    Curr Pharm Des; 2007; 13(3):333-46. PubMed ID: 17313364
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Neutrophil elastase as a target in lung cancer.
    Moroy G; Alix AJ; Sapi J; Hornebeck W; Bourguet E
    Anticancer Agents Med Chem; 2012 Jul; 12(6):565-79. PubMed ID: 22263788
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Protein Arginine Methyltransferases (PRMTs): promising targets for the treatment of pulmonary disorders.
    Zakrzewicz D; Zakrzewicz A; Preissner KT; Markart P; Wygrecka M
    Int J Mol Sci; 2012 Sep; 13(10):12383-400. PubMed ID: 23202904
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Year in review 2012: acute lung injury, interstitial lung diseases, sleep and physiology.
    Eves ND; Song Y; Piper A; Maher TM
    Respirology; 2013 Apr; 18(3):555-64. PubMed ID: 23336426
    [No Abstract]   [Full Text] [Related]  

  • 60. Matrix metalloproteases: underutilized targets for drug delivery.
    Vartak DG; Gemeinhart RA
    J Drug Target; 2007 Jan; 15(1):1-20. PubMed ID: 17365270
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.